Exeporfinium chloride

Drug Profile

Exeporfinium chloride

Alternative Names: XF-73

Latest Information Update: 07 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Destiny Pharma
  • Class Antibacterials; Porphyrins; Small molecules
  • Mechanism of Action Cell membrane modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Staphylococcal infections

Most Recent Events

  • 05 Sep 2016 Efficacy data from a phase I/II trial in Staphylococcal infections released by Destiny Pharma
  • 01 Apr 2016 Destiny Pharma completes a phase I/II trial in Staphylococcal infections in USA (Intranasal) (NCT01592214)
  • 11 Nov 2015 Exeporfinium chloride receives Qualified Infectious Disease Product status for Staphylococcal infections in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top